Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 20, 2022

SELL
$57.56 - $82.54 $184,134 - $264,045
-3,199 Closed
0 $0
Q4 2021

Feb 02, 2022

SELL
$72.5 - $100.68 $136,662 - $189,781
-1,885 Reduced 37.08%
3,199 $249,000
Q3 2021

Oct 28, 2021

SELL
$90.24 - $124.05 $24,003 - $32,997
-266 Reduced 4.97%
5,084 $485,000
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $141,520 - $210,436
1,511 Added 39.36%
5,350 $665,000
Q1 2021

May 06, 2021

BUY
$116.57 - $155.01 $2,797 - $3,720
24 Added 0.63%
3,839 $506,000
Q4 2020

Feb 09, 2021

BUY
$99.61 - $142.12 $16,037 - $22,881
161 Added 4.41%
3,815 $505,000
Q3 2020

Nov 03, 2020

SELL
$72.92 - $102.01 $34,637 - $48,454
-475 Reduced 11.5%
3,654 $373,000
Q2 2020

Jul 31, 2020

BUY
$55.75 - $92.75 $669 - $1,113
12 Added 0.29%
4,129 $359,000
Q1 2020

May 01, 2020

BUY
$37.9 - $104.44 $14,894 - $41,044
393 Added 10.55%
4,117 $239,000
Q4 2019

Feb 03, 2020

SELL
$77.66 - $99.74 $84,960 - $109,115
-1,094 Reduced 22.71%
3,724 $344,000
Q3 2019

Nov 01, 2019

BUY
$90.37 - $122.49 $107,359 - $145,518
1,188 Added 32.73%
4,818 $435,000
Q2 2019

Aug 01, 2019

SELL
$89.51 - $118.04 $43,143 - $56,895
-482 Reduced 11.72%
3,630 $428,000
Q1 2019

May 01, 2019

SELL
$61.98 - $96.5 $59,996 - $93,412
-968 Reduced 19.06%
4,112 $356,000
Q4 2018

Jan 31, 2019

SELL
$56.04 - $82.66 $10,759 - $15,870
-192 Reduced 3.64%
5,080 $321,000
Q3 2018

Nov 07, 2018

BUY
$48.29 - $80.6 $7,243 - $12,090
150 Added 2.93%
5,272 $416,000
Q4 2017

Feb 07, 2018

SELL
$46.49 - $60.51 $52,719 - $68,618
-1,134 Reduced 18.13%
5,122 $269,000
Q3 2017

Nov 06, 2017

BUY
$37.05 - $47.12 $231,784 - $294,782
6,256
6,256 $295,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.